Vinva Investment Management Ltd Reduces Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Vinva Investment Management Ltd lowered its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 14.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 187,064 shares of the company’s stock after selling 30,656 shares during the quarter. Vinva Investment Management Ltd’s holdings in Teva Pharmaceutical Industries were worth $4,175,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Smithfield Trust Co boosted its holdings in Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after acquiring an additional 980 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at $50,000. Ameliora Wealth Management Ltd. purchased a new position in Teva Pharmaceutical Industries during the 4th quarter valued at $66,000. IFP Advisors Inc boosted its holdings in Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock valued at $88,000 after acquiring an additional 1,960 shares during the period. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in Teva Pharmaceutical Industries during the 4th quarter valued at $104,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling

In related news, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares of the company’s stock, valued at $15,296,950. This represents a 29.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.55% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on TEVA shares. Barclays dropped their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday. Bank of America lowered their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, March 6th. UBS Group lowered their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. Finally, Piper Sandler upped their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Trading Down 1.2 %

Shares of NYSE TEVA opened at $16.29 on Thursday. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The stock has a market capitalization of $18.46 billion, a P/E ratio of -11.23, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries Limited has a 1-year low of $12.51 and a 1-year high of $22.80. The business has a fifty day moving average price of $17.99 and a 200 day moving average price of $18.25.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.